**CONCISE REPORT**

Filaggrin related antibodies among the aged

T Palosuo, R Tilvis, T Strandberg, K Aho

Background: The mean age at onset of new cases of rheumatoid arthritis (RA) has increased markedly. Because the prevalence of false positive rheumatoid factor reactions increases with advancing age, the diagnostic value of this test has limitations among the aged.

Objective: To study the occurrence of two filaggrin related antibodies in an aged population.

Methods: The study covered 300 subjects aged 78–88 years, one of whom had RA. The sera were tested with enzyme linked immunosorbent assays (ELISAs), using filaggrin purified from human skin and citrullinated cyclic peptide (CCP) as antigens.

Results: One patient with RA was positive for both antibodies. When the cut off level for positive reactions was set at the 98th centile of healthy blood donors, 24 (8%) of the other subjects were positive for antibodies against filaggrin, but only one against CCP.

Conclusion: The test for anti-CCP antibody has better specificity than the test for antibodies against filaggrin among the aged.

Rheumatoid arthritis (RA) is associated with several autoantibodies specific enough to serve as diagnostic and prognostic markers. Most information is available, by far, on rheumatoid factor (RF). Depending on the test techniques, RF can be detected in 60–80% of sera from patients with RA. RF is by no means specific for RA, positive reactions occurring transiently in connection with infections, immunisations, and a number of other conditions. Depending on the test systems used, 1–5% of healthy subjects are RF positive.

There has been a marked increase in the mean age of new patients with RA. Accordingly, diseases of the elderly associated with false positive RF reactions due to age, such as osteoarthritis and polymyalgia rheumatica, will assume increasing roles in the differential diagnosis of RA.

A number of autoantibodies target (pro)filaggrin or its components. These autoantibodies, comprising antikeratin antibody, antiperinuclear factor, antibodies against filaggrin purified from human skin or recombinant deiminated filaggrin, and antibodies against filaggrin derived synthetic peptides, occur in 30–70% of RA sera. Tests for antikeratin antibody and antiperinuclear factor are based on immunofluorescence, and these tests will soon be of historical interest only. Linear synthetic peptides have frequently proved to be disappointing in diagnostic work. Peptide cyclisation resulted in higher specific binding from RA sera and a somewhat higher frequency of positive reactions than the use of linear peptides. Commercial test kits are now available for the citrullinated cyclic peptide (CCP) antibody. Compared with RF testing, testing for anti-CCP antibody yields markedly fewer false positive reactions in patients with rheumatic diseases other than RA and in patients with various infectious diseases.

No corresponding information is available for antibodies against the entire filaggrin molecule.

The prevalence of positive RF reactions increases with advancing age. In the work described here we wanted to study whether the increase in the prevalence of antibodies associated with RA in healthy elderly people is a more general phenomenon and tested sera from elderly subjects for antibodies against filaggrin purified from human skin and for anti-CCP antibody.

Abbreviations: AFA, antifilaggrin antibodies; CCP, citrullinated cyclic peptide; HPLC, high performance liquid chromatography; RA, rheumatoid arthritis; RF, rheumatoid factor
SUBJECTS AND METHODS
Aged people, patients with RA, and control subjects

The Helsinki Aging Study is a population based joint study of general and specialised health care in the City of Helsinki, Finland. In 1990, 629 randomly selected people aged 75, 80, and 85 years underwent a comprehensive clinical study. At entry, participants were examined clinically by a nurse, general practitioner, neurologist, and cardiologist. The clinical examinations have been described in detail earlier. The subjects were re-examined in 1993 (clinical examination including echocardiography), in 1995 (home visits), and in 1999 (home visits including tests for cognition). Serum samples of a random 300 people, taken in 1993 and stored at −20°C, were available for the present study. Serum samples of 33 patients with active RA were obtained from Professor Marjatta Leirisalo-Repo, Department of Medicine, Helsinki University Hospital. Serum samples from 67 middle aged blood donors served as controls.

Antifilaggrin antibody (AFA) and RF determination

Filaggrin was purified from human epidermis as previously described. Briefly, proteins extracted from the epidermis were separated by reversed phase high performance liquid chromatography (HPLC). Fractions containing filaggrin, identified using monoclonal AFA, were then subjected to gel filtration HPLC and, finally, to a second reversed phase HPLC step. Amino acid sequencing and mass spectrometry of internal tryptic peptides were used to confirm the identity of the purified protein.

Enzyme linked immunosorbent assay (ELISA) for AFA was performed as described in detail elsewhere. Briefly, microtitre plates (Nunc, Roskilde, Denmark) were coated with filaggrin (3 µg/ml in 50 mM carbonate buffer, pH 9.6) and then coated with 1% human serum albumin. Sera were diluted 1:500 and binding of IgG class antibodies to solid phase filaggrin was demonstrated with alkaline phosphatase conjugated γ chain-specific antihuman IgG antibodies. The cut off level for positivity was set at the 98th centile for healthy controls, corresponding to about 8%. Only two anti-CCP positive cases were recorded. The one with the highest level had RA; the other had nothing that could explain the positive finding.

DISCUSSION

The prevalence of false positive RF reactions shows a progressive rise with advancing age, doubling during each 20 year
Filaggrin-related antibodies among the aged

When using sensitive test techniques, the prevalence is about 2% in the age group 15–34 years, 4% in the age group 35–54 years, 8% in the age group 55–74 years, and still higher at more advanced age. The increase is mainly due to IgM RF, with very little change in IgA RF. In line with published reports, the prevalence of false positive RF in the present series of 78–88 years old healthy subjects was 17%.

Our control group for AFA and anti-CCP determinations consisted of blood donors aged 40–65 years (mean 50), selected to represent ages of patients for whom immunological tests for RA are typically performed. When the cut off level for positive reactions in the AFA test was set at the 98th centile of controls, about 8% of the elderly subjects yielded false positive reactions—that is, the prevalence was fourfold compared with the controls. For the determination of AFA, we used filaggrin purified from human skin as an antigen. Sufficiency of the sera from aged subjects differ from those recognised by sera from patients with RA. Whatever the reason, we conclude that the test for anti-CCP has better specificity than the test for AFA among the aged.

ACKNOWLEDGEMENT

The authors thank Ms Maria Kiikeri and Ms Pirjo Mäki, RN, for excellent technical assistance.

Authors’ affiliations

T Palosuo, K Aho, National Public Health Institute, Helsinki, Finland
R Tilvis, T Strandberg, Department of Medicine, Helsinki University Hospital, Helsinki, Finland

Correspondence to: Professor T Palosuo, National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland; timo.palosuo@ktl.fi

Accepted 3 July 2002

REFERENCES

Filaggrin related antibodies among the aged

T Palosuo, R Tilvis, T Strandberg and K Aho

doi: 10.1136/ard.62.3.261

Updated information and services can be found at:
http://ard.bmj.com/content/62/3/261

These include:

References
This article cites 14 articles, 4 of which you can access for free at:
http://ard.bmj.com/content/62/3/261#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Connective tissue disease (4253)
Degenerative joint disease (4641)
Immunology (including allergy) (5144)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/